ADHERENCE, PERSISTENCE AND DEGREE OF BLOOD PRESSURE CONTROL ASSOCIATED TO INCIDENCE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH HYPERTENSION TREATED WITH FIXED COMBINATIONS: PP.5.206:

–3.4mmHg for OM/HCTZ 40/12.5 mg vs OM 40 mg; –5.5mmHg for OM/ HCTZ 40/25 mg vs OM 40 mg. Treatment differences for SeSBP reductions: –5.3mmHg for OM/HCTZ 40/12.5 mg vs OM 40 mg; –9.0mmHg for OM/ HCTZ 40/25 mg vs OM 40 mg. p< 0.0001 for all comparisons. Figure). The largest BP reductions were achieved with OM/HCTZ 40/25 mg. These findings were confirmed by the response rates achieved with OM 40 mg and OM/HCTZ 40/12.5 and 40/25 mg (24.8, 39.7 and 40.2%, respectively).